<DOC>
	<DOC>NCT00188812</DOC>
	<brief_summary>one year extension study following a previous double-blind study to evaluate safety of the drug</brief_summary>
	<brief_title>Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease</brief_title>
	<detailed_description>A one year extension study for patients who completed E2020-A001-319. Patients will receive 5my donepezil daily for the first 8 weeks and will be assessed by the incidence of advere events, changes in physical exams, ECG and clinical lab determinations. The results will be assessed 6 timues during the year. After 8 week, the investigator may increase the dose to 10mg/day if the patient if the patients show satisfactory tolerability. Six psychometric scales will also be evaluatd.</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>must have completed previous study E2020A001319 absence of a reliable caregiver clinically significant medical condition recent TIA</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>dementia</keyword>
	<keyword>stroke</keyword>
</DOC>